DYNAMICS MODELLING OF SWITCHING ADEFOVIR DIPIVOXIL TO ENTECAVIR ANTI-HBV INFECTION PERSONALIZED THERAPY

摘要

Adefovir dipivoxil (AD) is a potent inhibitor of hepatitis B virus (HBV). There are over 50% HBeAg-positive chronic hepatitis B (CHB) patients who respond the AD therapy. However clinical remission (low HBV DNA and Normal ALT) in 60% of patients who discontinued adefovir after 4～5 years. The aim of this study was to observe the efficacy of a patient's therapy for switching AD to Entecavir (EV), and modeling the viral dynamics. Based on a patient's AD and EV therapy clinic serum HBV DNA data, we propose an anti-HBV therapy dynamic model, and determine the model parameters. The numerical simulations of the model show that the calculated HBV DNA levels are agreement with in the patient's clinic serum HBV DNA data. The model predicts that if the patient's immune ability can be kept as the same as that in 172 weeks' follow up, the therapy benefit can continue, and all infected cells will be replaced by normal ones after 13.5 years.